The company is up by 0.70 percent from yesterday’s close. The stock is trading at $318.94 a bit higher than the 50 day moving average of $311.80 and a tad higher than the 200 day moving average of $264.06. The 50 day moving average was up $7.13 or +2.29% whereas the 200 day average was up by +20.78%.
Here is the rundown on market activity for C.R. Bard, Inc. (NYSE:BCR). Frank Jr Lupisella, VP disclosed the sale of 3,622 shares of BCR stock. The shares were purchased at an average price of $304.00. Lupisella now owns $3,082,162 of the stock according to the SEC filing. Group President Jim C. Beasley disclosed the sale of 4,390 shares. The shares were sold on February 21st for an average price of $245.00. The Group President now owns $5,447,575 of the stock per the Form 4 SEC filing.
Sr VP Christopher S. Holland sold 618 shares at an average price of $240.53 on Tue the 14th. That brings Holland’s holdings to $6,475,652 per an SEC filing yesterday.
C. R. Bard, Inc. (Bard), incorporated in 1923, is involved in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. The Company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company reports its sales in four product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. As of December 31, 2016, the Company, through its subsidiaries, marketed its products to customers in over 100 countries outside the United States. The Business’s principal international markets are in Europe, Japan and China..
These funds have also shifted positions in (BCR). As of the end of the quarter Shamrock Asset Management LLC had disposed of a total of 6 shares trimming its position 7.3%. The value in dollars went from $18,000 to $19,000 a change of $1,000 quarter over quarter. Mackenzie Financial Corp added to its position by buying 218,478 shares an increase of 1,323.0% as of 03/31/2017. Mackenzie Financial Corp now controls 234,992 shares with a value of $58,405,000. The total value of its holdings increased 1,404.1%.
As of quarter end Hm Payson & Co had bought 95 shares growing its stake by 9.4%. The value of the company’s investment in C.R. Bard, Inc. increased from $227,000 to $275,000 a change of 21.1% for the reporting period. Proficio Capital Partners LLC expanded its holdings by buying 5 shares an increase of 21.7% from 12/31/2016 to 03/31/2017. Proficio Capital Partners LLC claims 28 shares valued at $9,000. The value of the position overall is up by 80.0%.
On December 12 the stock rating was upgraded from “” to “Outperform” with a current price target of $245.00 in a report from BMO Capital. On September 16, 2016 the stock rating was changed to a “Outperform” in a report from Wells Fargo a boost from the previous “Market Perform” rating.
Equity analyst Evercore ISI Group initiated coverage on the stock giving it an initial rating of “Buy” and a price target of $235.00. July 27 investment analysts at JP Morgan held the company rating at “Equalweight” and raised the price target from $178.00 to $235.00.
On July 27 Jefferies left the company rating at “Equalweight” but raised the price expectation to $235.00 from $170.00. July 27 investment analysts at Citigroup left the stock rating at “Equalweight” but moved up the price target to $235.00 from $220.00.
The company also recently announced a dividend that will be paid on Friday the 4th of August 2017. The dividend will be $0.260 per share for the quarter or $1.04 on an annualized basis. The dividend yield will be $0.33. The ex-dividend date is Thursday the 27th of April 2017.
The company currently has a P/E ratio of 40.59 and the market cap of the company is 23.10B. In the last earnings report the EPS was $7.86 and is expected to be $11.78 for the current year with 72,417,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $2.99 with next year’s EPS anticipated to be $12.91.Advertisement